Abstract
Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.
Keywords: Cardiovascular disorders, myocardial infarction, RNAi, siRNA.
Current Pharmaceutical Design
Title:Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Volume: 21 Issue: 30
Author(s): Rahul Maheshwari, Muktika Tekade, Piyoosh A. Sharma and Rakesh Kumar Tekade
Affiliation:
Keywords: Cardiovascular disorders, myocardial infarction, RNAi, siRNA.
Abstract: Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.
Export Options
About this article
Cite this article as:
Maheshwari Rahul, Tekade Muktika, Sharma A. Piyoosh and Tekade Kumar Rakesh, Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders, Current Pharmaceutical Design 2015; 21 (30) . https://dx.doi.org/10.2174/138161282130151007150300
DOI https://dx.doi.org/10.2174/138161282130151007150300 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review
Mini-Reviews in Medicinal Chemistry Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy Perioperative Heart-Brain Axis Protection in Obese Surgical Patients: The Nutrigenomic Approach
Current Medicinal Chemistry Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry New Horizons in Diabetes Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets